A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...
BridgeBio Pharma (NASDAQ:BBIO) has reached a pivotal turning point following the FDA approval of Attruby (acoramidis), an ...
Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era ...
Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. More than one in seven people in the U.S. have ...
Some of us have a medicine cabinet that looks less like a pharmacy and more like a museum. It’s why I make a point to do an inventory at least once a year with my spring cleaning. You never know what ...
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.” By Simar Bajaj and Dani Blum When Jessica Layeux, a cybersecurity ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Certain medications, including antibiotics and SSRIs, ...
BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. A number of major drugmakers have reportedly raised the prices of hundreds of brand-name drugs, including some of the ...
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people
A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn’t use a patch. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results